# Zantac (ranitidine) litigation

> Educational mass tort overview from DrugsMonitor.com. Not legal or medical advice.

**Canonical URL:** https://drugsmonitor.com/case/zantac-ranitidine-lawsuit
**Last updated:** 2026-06-11

## Key facts

- **Matter:** Zantac / Ranitidine
- **Status:** Litigation concluded
- **Scope:** United States — national overview
- **Drug safety page:** https://drugsmonitor.com/drug-info/zantac-ranitidine-lawsuit

## Overview

Ranitidine (Zantac) litigation alleged that the molecule could form N-nitrosodimethylamine (NDMA) under certain conditions and that long-term use increased cancer risk. Regulatory agencies pulled many ranitidine products from the market in 2020.

### Procedural history

MDL No. 2924 centralized federal Zantac product liability cases. Daubert and preemption rulings significantly narrowed or ended many federal claims.

A small number of state-court paths may exist for limited scenarios; individualized legal research is required.

### Educational purpose

We retain this overview because patients still search for context on NDMA recalls and dismissed litigation. Nothing here promises a viable claim.

---

*DrugsMonitor.com is not a law firm. For medical decisions consult a licensed clinician; for legal decisions consult a qualified attorney.*